Poster

Poster

Interim Analysis of PROMise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib

Download PDF
Poster

OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Poster

OPN-9840, a non-covalent potent pan-TEAD inhibitor, exhibits single agent efficacy in preclinical malignant mesothelioma models

Download PDF
Poster

OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Poster

OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC

  • AUTHORS Matusow, et al
  • Programs OPN-6602
Download PDF
Poster

Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cancer

  • AUTHORS Swisher, et al
  • Programs OPN-2853
Download PDF
Poster

Phase 1b/2a Study of PLX2853, a Small Molecule BET Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

  • AUTHORS Gordon, et al
  • Programs OPN-2853
Download PDF
Poster

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Download PDF
Poster

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • AUTHORS Pemmaraju, et al
  • Programs OPN-2853
Download PDF
Poster

Phase 1b/2a Study of PLX51107, a Small Molecule BET Inhibitor, in Subjects with Advanced Hematological Malignancies and Solid Tumors

  • AUTHORS Patnaik, et al
  • Programs OPN-2853
Download PDF